Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olomorasib + Cetuximab + mFOLFOX6 in KRAS G12C-Mutant Colorectal Cancer
NCT07814417Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Primary completion
- Nov 2028
- Countries
- 3
01
Overview
A Phase 2 trial of olomorasib in colorectal cancer (CRC), sponsored by Eli Lilly and Company. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
olomorasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07814417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814417.